Jump Financial’s Anixa Biosciences ANIX Stock Holding History

Jump Financial’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-26,000	Closed	-$77K	–	1524
2021 Q4	$77K	Buy	+26,000	New	+$105K	﹤0.01%	1259

Other funds holding ANIX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Jump Financial's ANIX Position: Q1 2022 in Review

Jump Financial sold out of Anixa Biosciences (ANIX) in Q1 2022, closing a stake of 26,000 shares — an estimated $77K sold.

Jump Financial first reported a position in ANIX in Q4 2021 and held it in 1 quarter. The position peaked at $77K in Q4 2021. 41 funds tracked by Wall St. Rank hold ANIX as of Q1 2022.

Jump Financial reported no remaining Anixa Biosciences position as of Q1 2022 after selling out during the quarter.
Jump Financial sold 26,000 Anixa Biosciences shares in Q1 2022, an estimated $77K.
Jump Financial first reported a position in Anixa Biosciences in Q4 2021 and held it in 1 quarter.
Jump Financial's Anixa Biosciences position peaked at $77K in Q4 2021.
41 funds tracked by Wall St. Rank held Anixa Biosciences as of Q1 2022.

Based on Jump Financial's 13F filing for Q1 2022, filed 12 May 2022.